Hypertension
description
Transcript of Hypertension
![Page 1: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/1.jpg)
Hypertension
![Page 2: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/2.jpg)
Case 1
• A 31 year old Burmese male presents with shortness of breath x2 weeks. His blood pressure is 210/130 and he has evidence of volume overload. The creatinine is 2.0 and he has severe LV dysfunction on an echo.
![Page 3: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/3.jpg)
Case 1
• After initiating appropriate therapy, which of the following studies should you consider ordering next?– MRI of the renal arteries– 24 hour urine for catecholamines and
metanephrines– 24 urine for cortisol– Plasma renin activity and aldosterone levels
![Page 4: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/4.jpg)
Case 1
• What is the best first choice for management of this patients hypertension?– Hydrochlorothiazide– Lisinopril– Hydralazine, isosorbide mononitrate and
furosemide– Carvedilol and lisinopril– Diltiazem and furosemide
![Page 5: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/5.jpg)
Case 2
• A 55 year old male smoker recently diagnosed with diabetes presents for a follow-up office visit. His blood pressure on the last 3 visits has been 148/85, 152/89 and 148/92. He is asymptomatic. Laboratory studies and a urinalysis are unremarkable. An EKG shows sinus rhythm.
![Page 6: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/6.jpg)
Case 2
• What is the next best step in management of this patient?– Council him to loose weight, stop smoking and
exercise more– Start lisinopril 10 mg daily– Start hydrochlorothiazide 25 mg daily– Start metoprolol tartrate 25 mg BID– Order an echocardiogram for LV function
![Page 7: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/7.jpg)
HTN Is A Common And Costly Problem
• Most common reason for non-pregnant patients to visit MD office
• Most common reason for use of prescription drugs• 29-31% incidence in population > age 18• 56-65 million hypertensives vs 43.3 million in 1990• Only 34% have controlled blood pressure• Costs: 37 billion annually, 15.5 billion for Rx• Projected to affect 1.5 billion worldwide by 2025
Cutler. Hypertension. 2008.ALLHAT. JAMA. 2002.Kearny. Lancet. 2005.
![Page 8: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/8.jpg)
HTN Is Associated With Significant Morbidity
• Estimated lifetime risk of HTN is 90%• Most common modifiable risk factor for
– MI– Stroke– Aortic dissection– Heart failure – Atrial fibrillation– Peripheral arterial disease
Vasan. JAMA. 2002.
![Page 9: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/9.jpg)
Definitions
• Normal blood pressure– SBP < 120 and DBP < 80
• Prehypertension– SBP 120-139 or DBP 80-90
• Hypertension– Stage I: SBP 140-159 or DBP 80-89– Stage 2: SBP > 160 or DBP > 100
![Page 10: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/10.jpg)
Age Related Changes in Blood Pressure
Burt. Hypertension. 1995.
![Page 11: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/11.jpg)
HTN Is A Risk Factor For Death Worldwide
http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf
![Page 12: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/12.jpg)
HTN Is A Top Risk Factor For Death At Every Income Level
http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf
![Page 13: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/13.jpg)
Global Mortality and Disease and Risk Factor Burden: Age 30
![Page 14: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/14.jpg)
HTN Compounds Risk Regardless Of The Presence Of Other Risk Factors
Chobanian. JAMA. 2003.
![Page 15: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/15.jpg)
Heart Disease Risk Increases With Minimal BP Elevation
Chobanian. JAMA. 2003.
![Page 16: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/16.jpg)
Stroke Risk Increases With Minimal BP Elevation
Chobanian. JAMA. 2003.
![Page 17: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/17.jpg)
Minimal BP Elevation Is Associated With Increased Mortality
Chobanian. JAMA. 2003.
![Page 18: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/18.jpg)
HTN Treatment And Awareness In the US Has Improved
Kotchen. Circulation. 2010
![Page 19: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/19.jpg)
Reduction Blood Pressure Leads to Clinical Benefits
Law. BMJ. 2009.
![Page 20: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/20.jpg)
Physiology of Vascular Control• Goal: Maintain blood flow to important organs
– Local tissue controls and overall adjustments of cardiac pumping and vascular tone
• Short term blood pressure control– Cardiac output=Stroke volume x HR– Mechanisms
• Arterial baroreceptors, chemoreceptors, CNS (brain ischemia)• Fluid shifts, RAS activation, vasodilator systems
• Long term blood pressure control– Pressure natriuresis and diuresis– Infinite gain feedback control– All hypertension somehow alters this mechanism
![Page 21: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/21.jpg)
Determinant of Blood Pressure
Klabunde. CV Physiology Concepts. 2005.
![Page 22: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/22.jpg)
Time Dependence of BP Control
Fuster. Hurst’s the Heart. 12th Ed.
![Page 23: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/23.jpg)
Mechanisms of HTN
Kaplan. Lancet. 2006.
![Page 24: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/24.jpg)
Sympathetic Nervous System
Libby. Braunwald’s Heart Disease. 8th Ed.
![Page 25: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/25.jpg)
Short Term BP Control
Mohrman. Cardiovascular Physiology. 6th Ed.
![Page 26: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/26.jpg)
Long Term BP Control: Volume
Mohrman. Cardiovascular Physiology. 6th Ed.
![Page 27: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/27.jpg)
Alternations In Sodium Handling Result In HTN
Fuster. Hurst’s the Heart. 12th Ed.
![Page 28: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/28.jpg)
Risk Factors: Essential Hypertension
• Black race• Family history• Salt intake• Excess alcohol intake• Obesity• Dyslipidemia• Personality traits
![Page 29: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/29.jpg)
Diagnosis• Screening
– Every two years in normal– Every year in SBP > 120– Diagnose after 3-6 measurements
• “White coat hypertension”– 20-25% of mild office hypertension
• Ambulatory BP monitoring– White coat HTN– Episodic HTN– Resistant to increasing medication– Hypotensive symptoms on treatment– Autonomic dysfunction
![Page 30: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/30.jpg)
Initial Assessment
• Extent of target organ damage• Assess overall cardiovascular risk• Rule out modifiable causes of HTN• History and physical• Studies
– EKG– Labs: UA, Hgb, Gluc, Cr, K+, Na+, lipids
![Page 31: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/31.jpg)
Suspect Secondary Causes of HTN
• Suggested by: age, history, exam, severity, lab findings
• Poor response to drug therapy• Previously controlled becomes resistant• Sudden onset
![Page 32: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/32.jpg)
Secondary Hypertension• Renal disease• Drugs and alcohol• Pheochromocytoma• Primary hyperaldosteronism• Renovascular• Cushings• Thyroid and parathyroid disease• Sleep disordered breathing• Coarctation of the aorta
![Page 33: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/33.jpg)
Hints to Secondary Causes• Renal disease
– Increased creatinine or abnormal UA• OCPs, NSAIDS, diet pills, decongestants, stimulants, stroids,
herbals, calcineurin inhbitors, antidepressants• Pheochromocytoma
– HTN (paroxysmal), HA, palpitations, sweating• Primary aldosteronism
– Hypokalemia• Cushings
– Cushingoid facies, central obesity, proximal muscle weakness, ecchymosis
• Sleep apnea– Snoring and apnea, daytime somnolence, morning confusion ,
depression• Coarctation
– UE HTN, brachial-femoral delay, LW hypotension• Hypothyroidism and hyperparathyroidism
![Page 34: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/34.jpg)
Screening Tests for Secondary Causes
![Page 35: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/35.jpg)
Pheochromocytoma• Paroxysmal hypertension
in 50% of pheo patients• Present in about 0.2% of
patients with HTN• Headache, palpitations,
perspiration, pallor• Screen with 24 urine
– Metanephrines– Epinepherine
• Treat with surgeryVerrijcken. Am J Card. In Press.
![Page 36: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/36.jpg)
Renal Artery Stenosis• Most common after obesity and
EtOH• Rare in mild HTN, 10-45% of
severe HTN• Renal artery stenosis
– HTN age < 30 without family history, severe HTN with onset after 55
– Abdominal bruit– Accelerated HTN– Progressively resistant HTN– Flash pulmonary edema– RF of uncertain etiology– ARF after ACE-I– Asymmetric kidney size
• Screen with RA CT, US or MRI• Treatment
– Medical – Angioplasty or stenting
Zhang. Progress in CV disease. 2009
![Page 37: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/37.jpg)
Hyperaldosteronism• 10-20% in resistant HTN• 50% normokalemic • Screen
– Plasma renin activity (low)– Plasma aldo/renin (high)
• Confirmatory test• Surgery• Medical
– Mineralocorotoid antagonist
Kumar. Robbins and Cotran Pathologic Basis of Disease. 8th Ed.
![Page 38: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/38.jpg)
Coarctation Of The Aorta• 6-8% of all congenital heart
defects• More common in males• Associated with bicuspid valve,
Turners syndrome, other congenital heart disease and intracranial aneurysms
• BP and pulse variation• 75% mortality at 46 years if
uncorrected• CT, echo diagnosis • Surgical or percutaneous repair
Libby. Braunwald’s Heart Disease. 8th Ed.
![Page 39: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/39.jpg)
Sleep Apnea
• 15 million Americans affected
• Increased CV mortality• 50% of OSA have HTN• 30% of HTN have OSA• BP improves with OSA Tx
Somers. JACC, 2008.
![Page 40: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/40.jpg)
Goals of Therapy
• Reduce cardiovascular and renal morbidity and mortality
• Treat to goal < 140/90• For diabetics and heart disease, <130/80
![Page 41: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/41.jpg)
Benefits of Blood Pressure Lowering
• For stage I HTN (140-159/90-99) and one risk factor, sustained 12 mmHg lowering over 10 years prevents one death per 11 patients
Outcome Reduction
Stroke 35-40%
Heart failure >50%
Myoocardial infarction
20-25%
Chobanian. JAMA. 2003.
![Page 42: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/42.jpg)
Lifestyle ModificationIntervention Recommendation SBP Reduction
Weight reduction Normal body weight (BMI 18.5-24.9)
5-20 mmHg/10 kg
DASH Diet High fruit/veg, low fat 8-14 mmHg
Low salt diet Less than 6 g NaCl 2-8 mmHg
Physical activity 30 min daily 4-9 mmHg
Moderate alcohol
≤2/1 drink/day M/F 2-4 mmHg
Chobanian. JAMA. 2003.
![Page 43: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/43.jpg)
Effects Of Lifestyle Interventions On HTN: Premier Trial
Premier Collborative Group. JAMA, 2003.
![Page 44: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/44.jpg)
Salt Reduction
Bibbins-Domingo. NEJM. 2010.
![Page 45: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/45.jpg)
Approach to Medical Therapy• Major drug categories
– Thiazide diuretics– ACE-I or ARB– Calcium channel blockers– Beta blockers– Direct Vasodilators
• Blood pressure reduction is important NOT agent used• Wide interpatient variability in response to therapy• Find regimen that is most effective with fewest side
effects• Why we don’t succeed: lack of lifestyle modification,
inadequate drug dose, inappropriate drug combinations
![Page 46: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/46.jpg)
ALL HAT Trial
• Designed to compare older cheaper agents with newer ones
• 33,357 subjects 55 or older• HTN and one additional cardiac RF• Randomly assigned to chlorthalidone,
amlodipine, lisinopril or doxazosin• Doxazosin stopped early for increased CHF• Primary outcome: fatal heart disease or non-
fatal MIALLHAT. JAMA. 2002.
![Page 47: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/47.jpg)
Thiazide Diuretics First Are Best: ALLHAT
• Chlorthalidone– Lower heart failure than amlodipine and lisinopril– Lower combined CV disease than lisinopril– Benefits likely secondary to better BP control
• Chlorthalidone is different than HCTZ– Different potency and duration of action
![Page 48: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/48.jpg)
Blood Pressure Achieved: ALLHAT
ALLHAT. JAMA. 2002.
![Page 49: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/49.jpg)
CAD Mortality and Non-Fatal MI: ALLHAT
ALLHAT. JAMA. 2002
![Page 50: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/50.jpg)
Primary Endpoint: ACCOMPLISH
Jamerson. NEJM. 2008.
![Page 51: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/51.jpg)
Initial Monotherapy
• Unlikely to be effective if BP > 20/10 over goal• 60% of patients in ALLHAT required 2 drugs
![Page 52: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/52.jpg)
Factors Affecting Choice of Initial Therapy
Agent Indication Precautions
ACE-I LV dysfunction, post MI, DM, proteinuria
Diuretics (loop) Heart failure Hypokalemia
CCB (non-dihydropyridine)
Rate control in AF, angina, reactive airway disease
Beta Blockers Post MI, HF, AF, Ishchemia ↑ stroke, CV events, diabetes in age > 60
Alpha Blockers Prostatism Increased HF and CV events
![Page 53: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/53.jpg)
Sequential Monotherapy
• Largest benefit with initial low dose• Higher doses with marginal increased benefit
and increase AEs• Normalization with one drug in 30-50% of
patients with mild HTN• If not responsive to one, 50% chance or
response to another
![Page 54: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/54.jpg)
Comparison of Two Drug Regimens: ACCOMPLISH
• 11, 506 patients• Randomized to benez + HCTZ or amlodipine
Jamerson. NEJM. 2008.
![Page 55: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/55.jpg)
Blood Pressure Control Achieved: ACCOMPLISH
Jamerson. NEJM. 2008.
![Page 56: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/56.jpg)
ACCOMPLISH: ACE-I and CCB Was Superior
Jamerson. NEJM. 2008.
![Page 57: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/57.jpg)
Combination Therapy
• Long acting dihydropyridine + ACE-I/ARB• Consider stopping thiazide
![Page 58: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/58.jpg)
Strategy for HTN Management
Libby. Braunwald’s Heart Disease. 2007.
![Page 59: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/59.jpg)
Thiazides• Inhibits Na absorption in
DCT -> short term reduction in plasma volume
• Vasodilation long term• Adverse effects
– Erectile dysfunction– Hyperuricemia/gout– Hypo Na/K/Mg– Inc gluc or cholesterol– Sexual/sleep dysfunction
• Less effective with GFR <30
Libby. Braunwald’s Heart Disease. 2007.
![Page 60: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/60.jpg)
Other Diuretics• Loop diuretics
– Useful in volume overload states
– Renal dysfunction• Aldo antagonists
– Hyperaldo• Amiloride
– K Sparing• Adverse effects
– Dig and Li toxicity– Inhibited by NSAIDS
![Page 61: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/61.jpg)
Beta Antagonists
• Reduction in heart rate, contractility, cardiac output
• Reduction in renin release
• Initial drop in cardiac output, long term reduction in peripheral vascular resistance
Libby. Braunwald’s Heart Disease. 2007.
![Page 62: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/62.jpg)
Calcium Channel Blockers
• Inhibit entry of calcium into smooth muscle through L-type channels
• DHP vs Non-DHP• Non-DHP:
contrainidcations– AV block– LV dysfunction
Epstein. NEJM, 1982.
![Page 63: Hypertension](https://reader036.fdocuments.us/reader036/viewer/2022062520/5681651e550346895dd79cd9/html5/thumbnails/63.jpg)
ACE-Inhibitors or Angiotensin Receptor Blockers
• Inhibit angiotensin II or block its receptor
• Adverse effects– Hyperkalemia– Angioedema– Cough (4-10%)– Renal dysfunction
Zaman. Nature Reviews, 2002.